Lysergic acid diethylamide (3 x 100 µg LSD in three weeks, per os) followed by Placebo

Placebo (3 x 1 vial looking like LSD in three weeks, per os) followed by Lysergic acid diethylamide

Cluster Headache

Lysergic Acid Diethylamide

placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks

Placebo

Clinical Pharmacology & Toxicology, University Hospital Basel

Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache

Safety and Efficacy of Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache: a Randomized, Double-blind, Placebo-controlled Phase II Study

assessed with a standardized headache diary, within-subjects analysis

assessed with a standardized headache diary

assessment with the validated 36-item short-form health survey (SF-36), which measures health-related quality of life

assessment with the 5-level EuroQoL-5D (EQ-5D-5L), which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life

assessment with the Headache Impact Test (HIT-6), which measures the adverse impact of headache on social functioning, role functioning, vitality, cognitive functioning and psychological distress.

systolic and diastolic blood pressure in mmHg

assessment of subjective effects using visual analogue scales

assessed with the states of consciousness questionnaire (SCQ)

assessed with the 5-dimensions of altered states of consciousness questionnaire (5D-ASC)

assessment of persisting effects with the persisting effects questionnaire (PEQ) which assesses changes in attitude, mood, behavior and spiritual experience. The questionnaire will be completed at the beginning, after pulse regimens, and at the end of the study.

pre-post study comparison in all subjects, assessed with a standardized headache diary

between-subjects analysis before cross-over, assessed with a standardized headache diary

University Hospital, Basel, Switzerland

Double-blind, randomized, placebo-controlled two-phase cross-over study design.

Addiction

Prevalence of New Psychoactive Substances Use

Prevalence of New Psychoactive Substances Use Among Outpatient of Addiction Management Clinic in Assiut University Hospital

All participant will subjected to the following:
Special sheet designed for the study in department of neurology and psychiatry at Assiut University hospital asking about spychoactive substance use regarding to type, amount, duration,cause of use, and cause for stoppage.
Addiction severity index Urinary drug screen

AAEsraa

Princible investigator

Assiut University

Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.

Healthy

Capsules containing mannitol looking identical to LSD
per os

University Hospital Basel

Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study

repeated assessment of subjective effects with validated questionnaires

Effect on blood pressure, heart rate, body temperature, and pupillary function

Time course of plasma concentration, half-life, pharmacokinetic-pharmacodynamic relationship

Pre-Pulse inhibition of the acoustic startle reflex

Assessment of long-term psychological effects after 1 and 12 months

Effects of genetic polymorphisms on the response to LSD

assessment of cognitive and emotional empathy, as well as of prosocial behaviour

lysergic acid/cefaleia

Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache

Prevalence of New Psychoactive Substances Use

Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study

O mais completo banco de dados de ervas medicinais apoiado pela ciência